Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Radionuclide 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With MetastaticCastration Resistant Prostate Cancer (mCRPC)

NCT05150236 is registered in ClinicalTrials.gov with Australian and New Zealand Urogenital and Prostate Cancer Trials Group as lead sponsor.

NCT NCT05150236
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05150236 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Radionuclide 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With MetastaticCastration Resistant Prostate Cancer (mCRPC)
Lead sponsor
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Phase
Phase 2
Overall status
Unknown status
Start date
April 29, 2022
Completion date
December 31, 2024
Enrollment
93 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

genital neoplasms, male, neoplasms, neoplasms by site, prostate cancer, prostatic disease, prostatic neoplasms, urogenital neoplasms